Physician profile
David Macgregor
NPI 1235162447
$2,334.75
in general payments reported to CMS, 2019-2025
15 companies · $442 in 2025
The $442 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $275 · 2021: $233 · 2022: $253 · 2023: $446 · 2024: $431 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274 · Education: $45.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.28 |
| Education | $45.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $570.61 | 2021-2025 | Nemluvio |
| Abbvie INC. | $555.26 | 2021-2025 | |
| Pfizer INC. | $299.93 | 2022-2025 | |
| Lilly USA, LLC | $214.24 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $208.68 | 2019-2020 | |
| Incyte Corporation | $124.69 | 2023 | Opzelura |
| Janssen Scientific Affairs, LLC | $99.77 | 2019 | |
| Revance Therapeutics, INC. | $57.96 | 2024 | Daxxify |
| Biofrontera INC. | $54.43 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $31.85 | 2020-2021 | |
| Allergan, INC. | $29.41 | 2020-2021 | |
| Amgen INC. | $25.79 | 2019 | |
| Almirall LLC | $23.10 | 2023 | Klisyri |
| Arcutis Biotherapeutics, INC. | $22.09 | 2024 | Zoryve |
| Genzyme Corporation | $16.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Macgregor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.